Tags

Type your tag names separated by a space and hit enter

Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis.
BioDrugs. 2013 Feb; 27(1):75-81.B

Abstract

Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix(®)) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1 month post-vaccination, irrespective of their vaccination history. Seropositivity rates for antibodies against pertussis toxin had begun to decline by 5 years after a booster dose of Tdap in adolescents/adults, with a subsequent booster dose 10 years later generally as immunogenic and as well tolerated as the initial booster. Tdap was safe and well tolerated in all age groups.

Authors+Show Affiliations

Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand, bdr@adis.comNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23329401

Citation

Scott, Lesley J., and Paul L. McCormack. "Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (boostrix(®)): a Guide to Its Use as a Single-dose Booster Immunization Against Pertussis." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 27, no. 1, 2013, pp. 75-81.
Scott LJ, McCormack PL. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis. BioDrugs. 2013;27(1):75-81.
Scott, L. J., & McCormack, P. L. (2013). Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 27(1), 75-81. https://doi.org/10.1007/s40259-012-0009-y
Scott LJ, McCormack PL. Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (boostrix(®)): a Guide to Its Use as a Single-dose Booster Immunization Against Pertussis. BioDrugs. 2013;27(1):75-81. PubMed PMID: 23329401.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis. AU - Scott,Lesley J, AU - McCormack,Paul L, PY - 2013/1/19/entrez PY - 2013/1/19/pubmed PY - 2013/7/19/medline SP - 75 EP - 81 JF - BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy JO - BioDrugs VL - 27 IS - 1 N2 - Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix(®)) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1 month post-vaccination, irrespective of their vaccination history. Seropositivity rates for antibodies against pertussis toxin had begun to decline by 5 years after a booster dose of Tdap in adolescents/adults, with a subsequent booster dose 10 years later generally as immunogenic and as well tolerated as the initial booster. Tdap was safe and well tolerated in all age groups. SN - 1179-190X UR - https://www.unboundmedicine.com/medline/citation/23329401/Reduced_antigen_combined_diphtheria_tetanus_and_acellular_pertussis_vaccine_adsorbed__boostrix_®__:_a_guide_to_its_use_as_a_single_dose_booster_immunization_against_pertussis_ L2 - https://dx.doi.org/10.1007/s40259-012-0009-y DB - PRIME DP - Unbound Medicine ER -